论文部分内容阅读
目的:探讨患者bcr/abl融合基因检测在慢性粒细胞白血病(CML)治疗效果判断及微小残留病灶监测方面的价值。方法:应用RT蛳PCR方法定期检测羟基脲(Hu)联合α蛳干扰素(IFN蛳α)与异基因造血干细胞移植(allo蛳HSCT)治疗慢性粒细胞白血病患者前后bcr/abl融合基因表达情况。结果:IFN蛳α治疗组与allo蛳HSCT治疗组完全血液学缓解率分别为85.7 %、100 %,两者差异无显著性(P>0.01);两组分子生物学缓解率分别为9.52 %、87.5 %,差异有显著性(P<0.01)。结论:bcr/abl融合基因监测可以作为CML评价疗效的指标,适用于微小残留病变的监测。
Objective: To investigate the value of bcr / abl fusion gene detection in judging the therapeutic effect of chronic myeloid leukemia (CML) and monitoring of minimal residual disease. Methods: RT-PCR was used to detect the expression of bcr / abl fusion gene in patients with chronic myeloid leukemia before and after treatment with IFN-α and allogeneic hematopoietic stem cell transplantation (HSCT). Results: The complete hematological response rates were 85.7% and 100% in IFN 蛳 α group and allo 蛳 HSCT group, respectively. There was no significant difference between the two groups (P> 0.01). The rates of molecular biology remission were 9.52% 87.5%, the difference was significant (P <0.01). Conclusion: The monitoring of bcr / abl fusion gene can be used as an index to evaluate the curative effect of CML, which is suitable for the monitoring of minimal residual disease.